Advanced

Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer

Högberg, T LU ; Carstensen, J and Simonsen, E (1993) In Gynecologic Oncology 48(1). p.38-49
Abstract

The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for... (More)

The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for patients prescribed protocol treatment compared to 33% for those prescribed nonprotocol treatment (P < 0.0001). Stages III-IV patients prescribed protocol treatment had 23% 5-year survival compared to 11% for patients prescribed nonprotocol treatment (P < 0.0001). The impact of cis-platinum-based combination chemotherapy was thus not as pronounced as expected from clinical studies since many patients were not considered to be in a good enough general condition to receive cis-platinum. Multivariate Cox analysis of 223 cases showed that age (P < 0.0001), stage (P = 0.0002), grade of differentiation (P = 0.006), and postoperative residual tumor (P = 0.007) were independent prognostic factors. A prognostic index was developed which divided the patients into different risk groups. It was shown that high-risk patients identified by this index were mainly found in the group prescribed nonprotocol treatment and that the prognostic index could not be used to identify patients with a low probability of response among patients prescribed protocol treatment.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Age Factors, Aged, Aged, 80 and over, Carcinoma/pathology, Combined Modality Therapy, Female, Humans, Middle Aged, Multivariate Analysis, Neoplasm Staging, Ovarian Neoplasms/pathology, Prognosis, Survival Analysis, Treatment Outcome
in
Gynecologic Oncology
volume
48
issue
1
pages
12 pages
publisher
Academic Press
external identifiers
  • scopus:0027473723
ISSN
0090-8258
DOI
10.1006/gyno.1993.1007
language
English
LU publication?
no
id
60d284ec-ee46-45ca-8add-6ab8d66ac083
date added to LUP
2019-09-20 08:14:27
date last changed
2019-11-03 05:27:02
@article{60d284ec-ee46-45ca-8add-6ab8d66ac083,
  abstract     = {<p>The Swedish Tumor Registries are population based. Three hundred eighty-four patients with epithelial ovarian cancer registered in the Tumor Registry of the Southeast Health Care Region during the years 1984 to 1987 were reviewed; 332 patients were eligible for survival analysis. The protocol treatment during this period included primary surgery aimed at tumor reduction followed by combination chemotherapy (anthracyclin + cis-platinum, AP) in FIGO stages IC-IV. All patients treated otherwise were registered as prescribed nonprotocol treatment. An overall corrected 5-year survival of 40% was recorded. However, only 166/325 of the patients (51%) were actually prescribed protocol treatment as defined above. The 5-year survival was 49% for patients prescribed protocol treatment compared to 33% for those prescribed nonprotocol treatment (P &lt; 0.0001). Stages III-IV patients prescribed protocol treatment had 23% 5-year survival compared to 11% for patients prescribed nonprotocol treatment (P &lt; 0.0001). The impact of cis-platinum-based combination chemotherapy was thus not as pronounced as expected from clinical studies since many patients were not considered to be in a good enough general condition to receive cis-platinum. Multivariate Cox analysis of 223 cases showed that age (P &lt; 0.0001), stage (P = 0.0002), grade of differentiation (P = 0.006), and postoperative residual tumor (P = 0.007) were independent prognostic factors. A prognostic index was developed which divided the patients into different risk groups. It was shown that high-risk patients identified by this index were mainly found in the group prescribed nonprotocol treatment and that the prognostic index could not be used to identify patients with a low probability of response among patients prescribed protocol treatment.</p>},
  author       = {Högberg, T and Carstensen, J and Simonsen, E},
  issn         = {0090-8258},
  keyword      = {Adult,Age Factors,Aged,Aged, 80 and over,Carcinoma/pathology,Combined Modality Therapy,Female,Humans,Middle Aged,Multivariate Analysis,Neoplasm Staging,Ovarian Neoplasms/pathology,Prognosis,Survival Analysis,Treatment Outcome},
  language     = {eng},
  number       = {1},
  pages        = {38--49},
  publisher    = {Academic Press},
  series       = {Gynecologic Oncology},
  title        = {Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer},
  url          = {http://dx.doi.org/10.1006/gyno.1993.1007},
  volume       = {48},
  year         = {1993},
}